-+ 0.00%
-+ 0.00%
-+ 0.00%

Rezolute Inc. Announces Presentation of Phase 3 Study Baseline Data for Ersodetug in Treating Congenital Hyperinsulinism at ENDO 2025

Reuters·07/09/2025 11:30:19

Please log in to view news